Format

Send to

Choose Destination
J Pediatr Endocrinol Metab. 2005 Apr;18(4):385-93.

Three novel mutations in POU1F1 in Israeli patients with combined pituitary hormone deficiency.

Author information

1
Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children 's Medical Center of Israel, Petah Tiqva, Israel.

Abstract

BACKGROUND:

POU1F1, a pituitary-specific transcription factor of the class 1 POU family, is crucial for the development and differentiation of the anterior pituitary gland. Mutations in the POU1F1 gene have been shown to be responsible for a syndrome of combined pituitary hormone deficiency (CPHD), including prolactin, growth hormone and thyroid-stimulating hormone deficiencies.

METHODS:

Five patients with CPHD from three families were evaluated. The clinical and biochemical data were taken from the medical records. DNA was analyzed by polymerase chain reaction (PCR), denaturing gradient gel electrophoresis (DGGE), and sequencing.

RESULTS:

Molecular analysis yielded three novel mutations in POU1F1: W193X, Q242R (-2 bp), and F262L.

CONCLUSIONS:

Three novel POU1F1 mutations were detected in Israeli patients with CPHD. Two of them, a W193X missense mutation and a deletion of two adenine bases at position 242Q, may lead to the production of a truncated protein that lacks the entire POU homeodomain or part of it, respectively. The third mutation, F262L, resides in the POU homeodomain and hence might change the activity of the protein.

PMID:
15844473
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center